DHR beat Q1 expectations but the trajectory is mixed. Revenue reached $5.95B, up 3.7% YoY, and adjusted EPS was $2.06, up about 9.5% YoY. Core revenue growth was only +0.5%, down from +2.5% in Q4, but management raised FY2026 adjusted EPS guidance to $8.35-$8.55.

Key Metrics Trends

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Core revenue growth	-4.0%	-3.5%	0.5%	1.0%	-	1.5%	3.0%	2.5%	0.5%
Life Sciences core growth	7.5%	3.0%	5.0%	-2.0%	-1.5%	2.0%	3.5%	2.0%	-4.0%
Revenue	$5.8B	$5.7B	$5.8B	$6.5B	$5.7B	$5.9B	$6.1B	$6.8B	$6.0B
Revenue YoY %	-	-	-	-	-0.9%	+3.4%	+4.4%	+4.6%	+3.7%
Diluted EPS	-	$1.22	$1.12	-	$1.32	$0.77	$1.27	$1.67	$1.45
Diluted EPS YoY %	-	-	-	-	-	-36.9%	+13.4%	-	+9.8%
Free cash flow	$1.4B	$1.1B	$1.2B	$1.5B	$1.1B	$1.1B	$1.4B	$1.8B	$1.1B
Free cash flow YoY %	-	-	-	-	-26.8%	-3.3%	+11.7%	+17.6%	+2.4%

DHR is not yet a clean acceleration story. Reported revenue improved YoY and EPS beat, but core revenue growth decelerated meaningfully versus Q4 2025. The bull case depends on bioprocessing strength and productivity offsetting softer respiratory and China policy headwinds.

Beat/Miss

Guidance

Catalysts

Street Q&A

Contradictions

Read-Throughs

This Quarter vs Consensus

Metric	Consensus	Actual	Variance	Beat/Miss
Adjusted EPS	$1.94 preview consensus	$2.06	+$0.12 / +6.2%	Beat
Revenue	$5.73B Q1 2025 comp	$5.95B	+3.7% YoY	Beat signal
Core revenue growth	Positive low-single-digit expectation	+0.5%	Positive but decelerating	Mixed
Free cash flow	$1.06B Q1 2025 comp	$1.09B	+2.4% YoY	Small beat signal

Pattern: DHR is still beating EPS, but the revenue-quality signal is mixed. Q1 core revenue growth slowed from Q4, so beat magnitude is not clearly improving.

Guidance Deep Dive

Metric	Prior Guide	New Guide	Signal
FY2026 adjusted EPS	$8.35-$8.50	$8.35-$8.55	+$0.025 midpoint
Core revenue	3-6% FY framework from prior preview	Q1 actual +0.5%	Back-half recovery needed
China policy headwind	$200M expected headwind cited in Q1 materials	Still included in updated framework	Key watch item
Masimo deal	Pending acquisition	Still pending; strategic rationale unchanged	Capital allocation watch

Management tone was constructive despite mixed top-line quality. The transcript says strong Q1 performance supported raising adjusted EPS guidance, with better-than-expected productivity and bioprocessing strength offsetting headwinds. Source: DHR transcript 2026Q1.

Upcoming Catalysts

Catalyst	Timing	Consensus / Watch	Implication
Bioprocessing recovery	2026	Consumables and equipment order tone	Core reacceleration depends on this
Masimo acquisition close	H2 2026	Regulatory path and synergy confidence	Tests capital allocation credibility
China policy headwind	2026	$200M expected headwind	Could limit diagnostics recovery
Tariff/productivity offset	2026	Can productivity absorb costs?	EPS guide credibility variable

Street Q&A

Question	Management response	Assessment
Why is core growth only +0.5%?	Management cited steady recovery but respiratory and China policy as offsets.	Partly answered
Can EPS guide rise despite soft core growth?	Productivity and better bioprocessing drove the raise.	Well answered
Does Masimo change the DHR identity?	Management continues to frame the deal as DBS-applicable, but integration risk remains.	Needs tracking

Contradictions

Indirect Read-Throughs

Theme	Commentary	Read-through
Bioprocessing	DHR commentary was better than feared.	Positive read-through for life-science tools peers if order recovery continues.
China policy	$200M expected headwind remains material.	Negative read-through for diagnostics/tools with China exposure.
Tariffs	EPS guide still rose, implying productivity offsets.	Quality compounders may offset cost inflation faster than weaker peers.

Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.